A novel celecoxib analog UTX-121 inhibits HT1080 cell invasion by modulating membrane-type 1 matrix metalloproteinase

Biochem Biophys Res Commun. 2020 Jan 1;521(1):137-144. doi: 10.1016/j.bbrc.2019.10.092. Epub 2019 Oct 16.

Abstract

We designed and synthesized a celecoxib derivative UTX-121 to enhance its anti-tumor activity. Similar to celecoxib, this compound could also inhibit matrix metalloproteinase (MMP)-9 activity. In addition, UTX-121 suppressed membrane-type 1 MMP (MT1-MMP)-mediated pro-MMP-2 activation by disturbing the cell surface expression of MT1-MMP. UTX-121 also impeded the glycosylation of cell surface proteins, resulting in the suppression of cell attachment to fibronectin. This inhibition by UTX-121 caused the reduction of fibronectin-stimulated focal adhesion kinase activation, Akt activation, and cell migration. Consequently, UTX-121 treatment significantly inhibited fibronectin-induced HT1080 cell invasion into the Matrigel. UTX-121 may be a potent lead compound that can be used to develop a novel anti-tumor drug.

Keywords: COX; Cell adhesion; Invasion; MMP; MT1-MMP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / chemical synthesis
  • Anti-Inflammatory Agents, Non-Steroidal / chemistry
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Celecoxib / analogs & derivatives
  • Celecoxib / chemistry
  • Celecoxib / pharmacology*
  • Cell Adhesion / drug effects
  • Cell Survival / drug effects
  • Humans
  • Matrix Metalloproteinase 14 / metabolism*
  • Molecular Structure
  • Tumor Cells, Cultured

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • MMP14 protein, human
  • Matrix Metalloproteinase 14
  • Celecoxib